This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2017 Jul;16(7):490-491.

doi: 10.1016/S1474-4422(17)30163-1. Epub 2017 May 15.

Edaravone: a new treatment for ALS on the horizon?

Orla Hardiman¹, Leonard H van den Berg²

Affiliations

Affiliations

¹ Trinity Biomedical Sciences Institute Trinity College Dublin Ireland. Electronic address: hardimao@tcd.ie.
² University Medical Center Utrecht, Netherlands.

PMID: 28522180
DOI: 10.1016/S1474-4422(17)30163-1

Comment

Edaravone: a new treatment for ALS on the horizon?

Orla Hardiman et al. Lancet Neurol. 2017 Jul.

. 2017 Jul;16(7):490-491.

doi: 10.1016/S1474-4422(17)30163-1. Epub 2017 May 15.

Authors

Orla Hardiman¹, Leonard H van den Berg²

Affiliations

¹ Trinity Biomedical Sciences Institute Trinity College Dublin Ireland. Electronic address: hardimao@tcd.ie.
² University Medical Center Utrecht, Netherlands.

PMID: 28522180
DOI: 10.1016/S1474-4422(17)30163-1

No abstract available

PubMed Disclaimer

Comment on

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Writing Group, et al. Lancet Neurol. 2017 Jul;16(7):505-512. doi: 10.1016/S1474-4422(17)30115-1. Epub 2017 May 15. Lancet Neurol. 2017. PMID: 28522181 Clinical Trial.

Similar articles

Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
Bhandari R, Kuhad A, Kuhad A. Bhandari R, et al. Drugs Today (Barc). 2018 Jun;54(6):349-360. doi: 10.1358/dot.2018.54.6.2828189. Drugs Today (Barc). 2018. PMID: 29998226 Review.
Edaravone (Radicava) for ALS.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2017 Nov 6;59(1533):180-182. Med Lett Drugs Ther. 2017. PMID: 29125592 No abstract available.
Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP. WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):40-48. doi: 10.1080/21678421.2017.1361441. Amyotroph Lateral Scler Frontotemporal Degener. 2017. PMID: 28872915 Clinical Trial.
Edaravone for treatment of early-stage ALS.
Mora JS. Mora JS. Lancet Neurol. 2017 Oct;16(10):772. doi: 10.1016/S1474-4422(17)30289-2. Epub 2017 Sep 12. Lancet Neurol. 2017. PMID: 28920880 No abstract available.
Edaravone and its clinical development for amyotrophic lateral sclerosis.
Takei K, Watanabe K, Yuki S, Akimoto M, Sakata T, Palumbo J. Takei K, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):5-10. doi: 10.1080/21678421.2017.1353101. Amyotroph Lateral Scler Frontotemporal Degener. 2017. PMID: 28872907 Review.

See all similar articles

Cited by

Serotonergic Dysfunction in Amyotrophic Lateral Sclerosis and Parkinson's Disease: Similar Mechanisms, Dissimilar Outcomes.
Vermeiren Y, Janssens J, Van Dam D, De Deyn PP. Vermeiren Y, et al. Front Neurosci. 2018 Mar 20;12:185. doi: 10.3389/fnins.2018.00185. eCollection 2018. Front Neurosci. 2018. PMID: 29615862 Free PMC article.
Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System.
Vu M, Tortorice K, Zacher J, Dong D, Hur K, Zhang R, Good CB, Glassman PA, Cunningham FE. Vu M, et al. JAMA Netw Open. 2020 Oct 1;3(10):e2014645. doi: 10.1001/jamanetworkopen.2020.14645. JAMA Netw Open. 2020. PMID: 33017028 Free PMC article.
Rutin Ameliorates ALS Pathology by Reducing SOD1 Aggregation and Neuroinflammation in an SOD1-G93A Mouse Model.
Du X, Dong Q, Zhu J, Li L, Yu X, Liu R. Du X, et al. Int J Mol Sci. 2024 Sep 27;25(19):10392. doi: 10.3390/ijms251910392. Int J Mol Sci. 2024. PMID: 39408720 Free PMC article.
Exploring the genetics and non-cell autonomous mechanisms underlying ALS/FTLD.
Chen H, Kankel MW, Su SC, Han SWS, Ofengeim D. Chen H, et al. Cell Death Differ. 2018 Mar;25(4):648-662. doi: 10.1038/s41418-018-0060-4. Epub 2018 Feb 19. Cell Death Differ. 2018. PMID: 29459769 Free PMC article. Review.
Unraveling the Heterogeneity of ALS-A Call to Redefine Patient Stratification for Better Outcomes in Clinical Trials.
Tzeplaeff L, Jürs AV, Wohnrade C, Demleitner AF. Tzeplaeff L, et al. Cells. 2024 Mar 5;13(5):452. doi: 10.3390/cells13050452. Cells. 2024. PMID: 38474416 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Supplementary concepts

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal